Nursing Diagnosis Care Plan for Heart Failure: A Comprehensive Guide

Introduction

Heart failure (HF) is a pervasive and intricate clinical syndrome arising from various structural or functional cardiac disorders. This condition impairs the heart’s ability to effectively fill with or eject blood, thereby failing to meet the body’s metabolic demands. Heart failure is not a disease in itself but rather a consequence of underlying cardiac conditions. In the majority of cases, patients with heart failure exhibit symptoms stemming from compromised left ventricular function. Common clinical manifestations include dyspnea, fatigue, reduced exercise capacity, and fluid retention, often manifesting as pulmonary and peripheral edema.[1]

Heart failure due to left ventricular dysfunction is classified based on left ventricular ejection fraction (LVEF) into two primary categories: heart failure with reduced ejection fraction (HFrEF), where LVEF is 40% or less, and heart failure with preserved ejection fraction (HFpEF), where LVEF is greater than 40%.[2] Effective management of heart failure necessitates a holistic approach, with nursing care plans playing a pivotal role in optimizing patient outcomes and quality of life. This article delves into the essential nursing diagnoses and care planning strategies for patients with heart failure, aiming to equip healthcare professionals with the knowledge to deliver comprehensive and patient-centered care.

Common Nursing Diagnoses for Heart Failure

Nursing diagnoses are crucial for identifying patient problems and guiding the development of individualized care plans. For patients with heart failure, several nursing diagnoses are commonly relevant, reflecting the multifaceted impact of this condition on various body systems and functional abilities. These include:

• Decreased Cardiac Output: Reflects the heart’s inability to pump sufficient blood to meet the body’s metabolic needs.
• Activity Intolerance: Arises from the imbalance between oxygen supply and demand, leading to fatigue and dyspnea with exertion.
• Excess Fluid Volume: Results from the body’s compensatory mechanisms that lead to sodium and water retention.
• Risk for Impaired Skin Integrity: Increased risk due to edema, poor tissue perfusion, and immobility.
• Ineffective Tissue Perfusion: Reduced blood flow to peripheral tissues due to decreased cardiac output.
• Ineffective Breathing Pattern: Compromised respiratory function due to pulmonary congestion and fluid overload.
• Impaired Gas Exchange: Interference with oxygen and carbon dioxide exchange in the lungs due to pulmonary edema.
• Fatigue: Overwhelming and sustained exhaustion due to reduced cardiac output and metabolic changes.
• Anxiety: Emotional distress related to the chronic illness, symptoms, and prognosis of heart failure.

Causes of Heart Failure

Heart failure can be triggered by a wide array of disorders affecting different components of the cardiovascular system, including the pericardium, myocardium, endocardium, cardiac valves, vasculature, and metabolism. The underlying causes often differ between systolic dysfunction (HFrEF) and diastolic dysfunction (HFpEF).

Common causes of systolic dysfunction (HFrEF):

• Idiopathic Dilated Cardiomyopathy (DCM): A condition where the heart chambers enlarge and weaken without a clear identifiable cause.
• Coronary Heart Disease (Ischemic Heart Disease): Reduced blood flow to the heart muscle due to narrowed or blocked coronary arteries, often leading to myocardial infarction.
• Hypertension: Chronic high blood pressure that increases the workload on the heart, leading to myocardial hypertrophy and eventually dysfunction.
• Valvular Heart Disease: Conditions affecting the heart valves, such as stenosis or regurgitation, which can strain the heart and lead to failure.

Common causes of diastolic dysfunction (HFpEF):

• The causes listed above for systolic dysfunction can also contribute to diastolic dysfunction.
• Hypertrophic Obstructive Cardiomyopathy (HOCM): A genetic condition causing thickening of the heart muscle, which can impair ventricular filling.
• Restrictive Cardiomyopathy: A condition where the heart muscle becomes stiff and less elastic, hindering ventricular filling.

Risk Factors for Heart Failure

Identifying risk factors is crucial for prevention and early intervention strategies. Several factors significantly increase the likelihood of developing heart failure:

• Coronary Artery Disease (CAD): The most significant risk factor, as it reduces blood supply to the heart muscle.
• Myocardial Infarction (MI): Heart attack, which damages heart muscle and impairs its function.
• Hypertension: Long-term high blood pressure strains the heart.
• Diabetes Mellitus: Increases the risk of CAD and cardiomyopathy.
• Obesity: Associated with increased cardiovascular strain and risk factors like hypertension and diabetes.[17]
• Smoking: Damages blood vessels and increases the risk of CAD.
• Alcohol Use Disorder: Excessive alcohol consumption can lead to alcoholic cardiomyopathy.
• Atrial Fibrillation: An irregular heart rhythm that can worsen heart failure or contribute to its development.
• Thyroid Diseases: Both hyperthyroidism and hypothyroidism can strain the heart.[19]
• Congenital Heart Disease: Structural heart defects present at birth.
• Aortic Stenosis: Narrowing of the aortic valve, increasing the heart’s workload.

Assessment of Heart Failure

A thorough assessment is fundamental for identifying heart failure and guiding appropriate interventions. Assessment should encompass both subjective symptoms reported by the patient and objective clinical findings.

Common Symptoms:

Symptoms can be broadly categorized into those related to fluid overload and those related to reduced cardiac output.

Fluid Overload Symptoms:

• Dyspnea: Shortness of breath, particularly on exertion or lying flat.
• Orthopnea: Shortness of breath when lying flat, relieved by sitting or standing.
• Edema: Swelling in the ankles, legs, abdomen (ascites), or sacral area.
• Right Upper Quadrant Pain: Discomfort due to hepatic congestion.
• Abdominal Distension: From ascites (fluid accumulation in the abdominal cavity).

Reduced Cardiac Output Symptoms:

• Fatigue: Persistent and overwhelming tiredness.
• Weakness: Especially pronounced with physical activity.
• Anorexia: Loss of appetite due to poor organ perfusion and bowel edema.
• Dizziness or Lightheadedness: Due to reduced blood flow to the brain.

Characteristic Clinical Features:

• Pulsus Alternans: Alternating strong and weak peripheral pulses, indicative of left ventricular dysfunction.
• Displaced Apical Impulse: Laterally displaced point of maximal impulse, suggesting left ventricular enlargement.
• S3 Gallop: An abnormal heart sound in early diastole, a sensitive indicator of ventricular dysfunction.
• Peripheral Edema: Swelling in the extremities.
• Pulmonary Rales (Crackles): Abnormal lung sounds indicating fluid in the lungs.

New York Heart Association (NYHA) Functional Classification:

The NYHA classification is a widely used system to categorize the severity of heart failure based on symptoms and functional limitations:

• Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.
• Class II: Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
• Class III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.
• Class IV: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

Diagnostic Evaluation for Heart Failure

Various diagnostic tests are employed to evaluate heart failure, confirm the diagnosis, determine the underlying cause, and assess the severity of the condition.

• Electrocardiogram (ECG): To detect evidence of myocardial infarction, ischemia, arrhythmias (like atrial fibrillation), and conduction abnormalities.
• Chest X-ray: To assess cardiac size, pulmonary congestion (cephalization of pulmonary vessels, Kerley B-lines), and pleural effusions.

Alt text: Chest X-ray revealing signs of congestive heart failure, including cardiomegaly and pulmonary edema, crucial for nursing assessment and care plan development.

• Blood Tests:
  • Cardiac Troponin (T or I): To rule out acute myocardial infarction.
  • Complete Blood Count (CBC): To assess overall health and rule out anemia.
  • Serum Electrolytes: To evaluate electrolyte imbalances, especially sodium and potassium.
  • Blood Urea Nitrogen (BUN) and Creatinine: To assess renal function, which is often affected in heart failure.
  • Liver Function Tests (LFTs): To assess liver function, which can be impaired due to congestion.
  • Brain Natriuretic Peptide (BNP) or N-terminal pro-BNP (NT-proBNP): Elevated levels are highly indicative of heart failure and aid in diagnosis and prognosis.[41]
• Transthoracic Echocardiogram: The primary imaging modality to evaluate ventricular function (ejection fraction), valve function, chamber size, and hemodynamics.

Medical Management of Heart Failure

The medical management of heart failure is multifaceted and aims to alleviate symptoms, improve quality of life, slow disease progression, and reduce mortality. Pharmacological and device therapies are central to this approach.

Pharmacological Management:

Several classes of medications are used in the management of heart failure, often in combination, to target different pathophysiological mechanisms:

• Diuretics: Such as furosemide and hydrochlorothiazide, to reduce fluid overload and alleviate symptoms like edema and dyspnea.
• Beta-blockers: Such as metoprolol and carvedilol, to slow heart rate, reduce myocardial workload, and improve survival in HFrEF.
• Angiotensin-Converting Enzyme Inhibitors (ACEIs): Such as enalapril and lisinopril, to reduce afterload, promote vasodilation, and improve survival in HFrEF.
• Angiotensin Receptor Blockers (ARBs): Such as valsartan and losartan, used in patients who cannot tolerate ACEIs, with similar benefits.
• Angiotensin Receptor-Neprilysin Inhibitor (ARNI): Sacubitril/valsartan, which combines an ARB with a neprilysin inhibitor, shown to be superior to ACEIs in reducing mortality and hospitalization in HFrEF.[33, 47]
• Hydralazine and Isosorbide Dinitrate: A combination therapy particularly beneficial in African Americans with persistent NYHA class III-IV HFrEF despite optimal therapy.[3]
• Digoxin: To improve symptoms and control heart rate in certain patients, particularly those with atrial fibrillation and rapid ventricular response.
• Aldosterone Antagonists (Mineralocorticoid Receptor Antagonists – MRAs): Such as spironolactone and eplerenone, to reduce sodium and water retention and improve survival in HFrEF.
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Such as dapagliflozin and empagliflozin, initially developed for diabetes, but shown to reduce hospitalization and cardiovascular mortality in heart failure, regardless of diabetes status.

Device Therapy:

• Implantable Cardioverter-Defibrillator (ICD): To prevent sudden cardiac death due to ventricular arrhythmias, indicated for primary and secondary prevention in selected patients with HFrEF.
• Cardiac Resynchronization Therapy (CRT): Biventricular pacing to improve heart function and symptoms in patients with HFrEF, left bundle branch block, and prolonged QRS duration. Often combined with an ICD (CRT-D).
• Ventricular Assist Devices (VADs): Mechanical pumps to support heart function in severe heart failure, used as a bridge to transplant or as destination therapy in patients not eligible for transplant.
• Cardiac Transplantation: Heart replacement for end-stage heart failure patients who meet specific criteria.

Nursing Management and Care Plan for Heart Failure

Nursing care is integral to the comprehensive management of heart failure. A well-structured nursing care plan addresses the patient’s physical, emotional, and educational needs. Key components of a nursing care plan for heart failure include:

1. Nursing Diagnosis: Decreased Cardiac Output

• Goals: Improve cardiac output, reduce cardiac workload, and optimize tissue perfusion.
• Nursing Interventions:
  • Monitor Vital Signs: Regularly assess heart rate, blood pressure, respiratory rate, and oxygen saturation.
  • Assess Heart Sounds: Auscultate for abnormal heart sounds like S3 and S4 gallops, murmurs.
  • Monitor for Signs of Decreased Cardiac Output: Assess for fatigue, weakness, dizziness, chest pain, cool extremities, and decreased urine output.
  • Administer Medications as Prescribed: Ensure timely administration of medications like diuretics, ACEIs/ARBs/ARNIs, beta-blockers, and digoxin, and monitor for their effectiveness and side effects.
  • Promote Rest and Energy Conservation: Balance activity and rest periods to reduce cardiac workload.
  • Elevate Legs when Sitting: To promote venous return and reduce preload.
  • Monitor Fluid Balance: Accurately measure intake and output, daily weights, and assess for edema.

2. Nursing Diagnosis: Excess Fluid Volume

• Goals: Reduce fluid overload, alleviate symptoms of congestion, and prevent complications.
• Nursing Interventions:
  • Restrict Sodium Intake: Educate patients on a low-sodium diet (typically 2-3 grams per day) and provide dietary guidelines.
  • Fluid Restriction: Implement and monitor fluid restriction as prescribed (usually 1.5-2 liters per day).
  • Administer Diuretics as Prescribed: Monitor diuretic effectiveness (urine output, weight loss, reduction in edema) and watch for electrolyte imbalances (hypokalemia, hyponatremia).
  • Monitor Daily Weights: Instruct patients on daily weight monitoring at home and to report significant weight gain.
  • Assess for Edema: Regularly assess and document the location and severity of edema.
  • Monitor Respiratory Status: Assess for signs of pulmonary congestion (rales, dyspnea, orthopnea).
  • Elevate Head of Bed: To promote lung expansion and reduce orthopnea.

3. Nursing Diagnosis: Activity Intolerance

• Goals: Improve activity tolerance, reduce fatigue, and enhance functional capacity.
• Nursing Interventions:
  • Assess Activity Tolerance: Evaluate the patient’s current activity level and limitations.
  • Plan Rest Periods: Schedule rest periods between activities to prevent fatigue.
  • Gradual Increase in Activity: Encourage a gradual increase in activity level as tolerated, following a structured exercise program if appropriate.
  • Monitor Response to Activity: Assess vital signs, dyspnea, and fatigue levels before, during, and after activity.
  • Energy Conservation Techniques: Teach patients energy-saving techniques, such as pacing activities and prioritizing tasks.
  • Refer to Cardiac Rehabilitation: For structured exercise programs and education to improve cardiovascular fitness and self-management skills.

4. Nursing Diagnosis: Ineffective Breathing Pattern and Impaired Gas Exchange

• Goals: Optimize respiratory function, improve oxygenation, and reduce dyspnea.
• Nursing Interventions:
  • Monitor Respiratory Rate and Depth: Assess for tachypnea, labored breathing, and use of accessory muscles.
  • Auscultate Lung Sounds: Monitor for rales, wheezes, or diminished breath sounds.
  • Monitor Oxygen Saturation: Maintain oxygen saturation as prescribed (usually above 90%).
  • Administer Oxygen Therapy as Prescribed: Provide supplemental oxygen as needed to maintain adequate oxygenation.
  • Position Patient for Optimal Lung Expansion: Elevate the head of the bed, encourage frequent position changes, and assist with deep breathing and coughing exercises.
  • Monitor for Signs of Hypoxia: Assess for cyanosis, confusion, restlessness, and changes in mental status.

5. Nursing Diagnosis: Anxiety

• Goals: Reduce anxiety, promote emotional well-being, and enhance coping mechanisms.
• Nursing Interventions:
  • Assess Anxiety Level: Evaluate the patient’s level of anxiety and identify triggers.
  • Provide Emotional Support: Offer a calm and reassuring presence, actively listen to patient concerns, and validate their feelings.
  • Educate about Heart Failure and Management: Provide clear and understandable information about heart failure, treatment plan, and prognosis to reduce uncertainty and fear.
  • Teach Relaxation Techniques: Instruct patients in relaxation techniques such as deep breathing, guided imagery, and meditation.
  • Encourage Verbalization of Feelings: Create a safe space for patients to express their fears and anxieties.
  • Refer to Counseling or Support Groups: If needed, refer patients to mental health professionals or heart failure support groups.

6. Nursing Diagnosis: Risk for Impaired Skin Integrity

• Goals: Maintain skin integrity and prevent skin breakdown.
• Nursing Interventions:
  • Assess Skin Regularly: Inspect skin for redness, breakdown, and edema, especially in pressure areas.
  • Reposition Patient Frequently: Turn and reposition patients at least every 2 hours to relieve pressure.
  • Provide Pressure Relief: Use pressure-reducing mattresses, cushions, and heel protectors.
  • Maintain Skin Hygiene: Keep skin clean and dry, gently cleanse and moisturize skin.
  • Protect Edematous Skin: Avoid tape directly on edematous skin, and use skin protectants as needed.
  • Encourage Mobility: Promote mobility as tolerated to improve circulation and reduce pressure on skin.

When to Seek Help

Patients and caregivers should be educated on recognizing signs and symptoms that warrant prompt medical attention. These include:

• Worsening Dyspnea: Increased shortness of breath at rest or with minimal exertion.
• Increased Edema: Rapid weight gain, increased swelling in legs, ankles, or abdomen.
• Persistent Cough or Wheezing: Especially if accompanied by pink, frothy sputum.
• Chest Pain or Discomfort: New onset or worsening angina.
• Palpitations or Irregular Heartbeat: Change in heart rhythm or awareness of rapid heartbeats.
• Dizziness or Lightheadedness: Especially with activity or position changes.
• Unexplained Fatigue or Weakness: Significant increase in fatigue or inability to perform usual activities.
• Decreased Urine Output: Despite taking diuretics.
• Confusion or Change in Mental Status: New onset confusion or disorientation.

Monitoring Heart Failure

Continuous and vigilant monitoring is essential for managing heart failure effectively. Key aspects of monitoring include:

• Vital Signs: Regular monitoring of heart rate, blood pressure, respiratory rate, oxygen saturation, and temperature.
• Daily Weights: Essential for detecting fluid retention or loss.
• Intake and Output: To assess fluid balance, particularly important in patients on diuretics.
• Symptoms Assessment: Regularly assess for changes in symptoms such as dyspnea, fatigue, edema, and chest pain.
• Electrolyte Levels: Periodic monitoring of serum electrolytes, especially potassium and sodium, particularly in patients on diuretics and ACEIs/ARBs/MRAs.
• Renal Function: Monitor BUN and creatinine levels to assess kidney function.
• ECG Monitoring: Continuous or intermittent ECG monitoring to detect arrhythmias.
• BNP/NT-proBNP Levels: Serial measurements can help assess disease progression and response to therapy.

Coordination of Care

Effective heart failure management requires a collaborative, interprofessional team approach. The team typically includes:

• Primary Care Physician: For ongoing management and coordination of care.
• Cardiologist: For specialized cardiac care and management of heart failure.
• Cardiac Nurses: For patient education, medication management, symptom monitoring, and care coordination.
• Pharmacist: For medication management, drug interaction monitoring, and patient education on medications.
• Registered Dietitian: For nutritional counseling and dietary management, particularly sodium and fluid restriction.
• Social Worker or Case Manager: To assist with resources, support services, and discharge planning.
• Cardiac Rehabilitation Team: For structured exercise programs, education, and lifestyle modification support.

Health Teaching and Health Promotion

Patient education is a cornerstone of heart failure management. Nurses play a vital role in educating patients and their families on various aspects of self-care and disease management:

• Medication Management: Emphasize the importance of medication adherence, proper dosage, timing, and potential side effects.
• Daily Weight Monitoring: Teach patients how to monitor daily weight, recognize significant changes, and when to report weight fluctuations.
• Low-Sodium Diet: Provide detailed dietary guidelines on sodium restriction, reading food labels, and meal planning.
• Fluid Restriction: Explain fluid restriction guidelines, strategies for managing thirst, and types of fluids to avoid.
• Activity and Exercise Recommendations: Provide guidance on safe and appropriate levels of physical activity, emphasizing gradual progression and avoiding overexertion.
• Symptom Recognition and Management: Educate patients on recognizing worsening symptoms and when to seek medical attention.
• Smoking Cessation and Alcohol Moderation: Counsel patients on the risks of smoking and excessive alcohol consumption and provide resources for cessation and moderation.
• Importance of Follow-up Appointments: Emphasize the need for regular follow-up visits with healthcare providers.

Discharge Planning

Effective discharge planning is crucial for ensuring a smooth transition from hospital to home and preventing readmissions. Discharge planning should include:

• Medication Reconciliation and Education: Review all medications with the patient and caregiver, ensuring understanding of dosages, frequency, and side effects. Provide written medication lists.
• Dietary and Fluid Restriction Review: Reinforce dietary and fluid restriction guidelines and provide written materials.
• Activity Guidelines: Review activity recommendations and any limitations.
• Symptom Management Plan: Provide a clear plan for managing symptoms at home and recognizing warning signs.
• Follow-up Appointment Scheduling: Ensure follow-up appointments with primary care physician and cardiologist are scheduled.
• Referral to Home Health or Community Resources: Arrange for home health nursing visits or referrals to community support services as needed.
• Emergency Contact Information: Provide clear instructions on who to contact in case of emergencies or worsening symptoms.

Conclusion

Developing and implementing a comprehensive Nursing Diagnosis Care Plan For Heart Failure is essential for providing holistic and effective care. By focusing on key nursing diagnoses such as decreased cardiac output, excess fluid volume, activity intolerance, and anxiety, nurses can significantly impact patient outcomes and quality of life. Patient education, meticulous monitoring, interprofessional collaboration, and well-coordinated discharge planning are all vital components of optimal nursing management for individuals living with heart failure. Through diligent and patient-centered care, nurses play a crucial role in empowering patients to manage their condition effectively and live healthier, more fulfilling lives.

References

1.Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW., ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. [PubMed: 35363499]

2.Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78. [PMC free article: PMC4868779] [PubMed: 26935038]

3.CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429-35. [PubMed: 2883575]

4.Lind L, Ingelsson M, Sundstrom J, Ärnlöv J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart. 2021 Sep;8(2) [PMC free article: PMC8438838] [PubMed: 34518286]

5.Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019 Nov 19;9(1):17022. [PMC free article: PMC6863880] [PubMed: 31745178]

6.Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021 Oct;51(10):797-836. [PMC free article: PMC8484993] [PubMed: 34327881]

7.Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc Med. 2021 Apr;31(3):163-169. [PMC free article: PMC7965406] [PubMed: 33383171]

8.Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):819-837. [PubMed: 28912185]

9.Shams P, Ahmed I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Cardiac Amyloidosis. [PubMed: 35593829]

10.Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy. [PubMed: 30725919]

11.Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med Sci Monit. 2023 Mar 06;29:e939020. [PMC free article: PMC9999670] [PubMed: 36872594]

12.Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article: PMC8913320] [PubMed: 35281752]

13.Ahmad SA, Brito D, Khalid N, Ibrahim MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Takotsubo Cardiomyopathy. [PubMed: 28613549]

14.DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, Hsich E. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18;130(4):436-454. [PMC free article: PMC10361647] [PubMed: 35175847]

15.Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. [PubMed: 23850914]

16.Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):46-51. [PMC free article: PMC7691623] [PubMed: 33238736]

17.Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. [PMC free article: PMC10040794] [PubMed: 36993998]

18.Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep;49(9):808-817. [PMC free article: PMC6713829] [PubMed: 31456374]

19.Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc Health Risk Manag. 2010 Aug 09;6:473-7. [PMC free article: PMC2922308] [PubMed: 20730063]

20.Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, Suter PM, Vergopoulos A, Erne P. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012 Mar;101(3):159-64. [PubMed: 22057652]

21.DiNicolantonio JJ, Liu J, O’Keefe JH. Thiamine and Cardiovascular Disease: A Literature Review. Prog Cardiovasc Dis. 2018 May-Jun;61(1):27-32. [PubMed: 29360523]

22.Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016 Aug 02;68(5):473-482. [PubMed: 27470455]

23.Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014 Jul;8(3):308-15. [PMC free article: PMC4160726] [PubMed: 25221635]

24.Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 03;141(9):e139-e596. [PubMed: 31992061]

25.Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A. [PubMed: 8376698]

26.Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603. [PMC free article: PMC5408160] [PubMed: 28122885]

27.Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, Oguz A, Kruger IM, Diaz R, Yusoff K, Mony P, Chifamba J, Yeates K, Kelishadi R, Yusufali A, Khatib R, Rahman O, Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA, Teo KK, Leong D, O’Donnell M, McKee M, Dagenais G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07;395(10226):795-808. [PMC free article: PMC8006904] [PubMed: 31492503]

28.Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006 Jan 28;367(9507):356-67. [PubMed: 16443044]

29.Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. [PubMed: 22227365]

30.Ait Mou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob Cardiol Sci Pract. 2015;2015:10. [PMC free article: PMC4448074] [PubMed: 26779498]

31.Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. [PMC free article: PMC9553007] [PubMed: 36237903]

32.Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02;9(11):e015071. [PMC free article: PMC7428996] [PubMed: 32427034]

33.Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. [PMC free article: PMC8837825] [PubMed: 33004114]

34.Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. [PMC free article: PMC6899218] [PubMed: 31202759]

35.Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. [PMC free article: PMC4654630] [PubMed: 26250359]

36.Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 Jul;19(7):821-836. [PMC free article: PMC5734941] [PubMed: 28560717]

37.King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012 Jun 15;85(12):1161-8. [PubMed: 22962896]

38.Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, Sabbah HN, Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999 Dec;138(6 Pt 1):1133-9. [PubMed: 10577445]

39.Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005 May 17;111(19):2454-60. [PubMed: 15867182]

40.Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73. [PubMed: 22104551]

41.Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 Feb;13(2):e006541. [PubMed: 32065760]

42.Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Störk S. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):407-16. [PubMed: 16328851]

43.Jain S, Londono FJ, Segers P, Gillebert TC, De Buyzere M, Chirinos JA. MRI Assessment of Diastolic and Systolic Intraventricular Pressure Gradients in Heart Failure. Curr Heart Fail Rep. 2016 Feb;13(1):37-46. [PubMed: 26780916]

44.Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013 Aug 30;113(6):660-75. [PubMed: 23989711]

45.Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA., American Heart Association Get With the Guidelines-Heart Failure Program. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32. [PubMed: 20123668]

46.Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O’Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW., VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021 Nov 16;10(22):e021094. [PMC free article: PMC8751950] [PubMed: 34743540]

47.Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM., VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. [PubMed: 32222134]

48.Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec;140(6):840-7. [PubMed: 11099986]

49.Rider I, Sorensen M, Brady WJ, Gottlieb M, Benson S, Koyfman A, Long B. Disposition of acute decompensated heart failure from the emergency department: An evidence-based review. Am J Emerg Med. 2021 Dec;50:459-465. [PubMed: 34500232]